Antineoplastic agents and the liver
| Autor: | Daniel Dhumeaux, Felix Reyes, Daniel B. Ménard, Christian Gisselbrecht, Michel Marty |
|---|---|
| Rok vydání: | 1980 |
| Předmět: |
Alkylating Agents
Antimetabolites Antineoplastic Antibiotics Antineoplastic Hepatology Human studies Liver toxicity business.industry Gastroenterology Cancer Antineoplastic Agents medicine.disease Bioinformatics Antineoplastic Agents Phytogenic Hepatic Involvement Liver Pharmacokinetics Humans Medicine In patient Chemotherapeutic drugs Chemical and Drug Induced Liver Injury business Mode of action |
| Zdroj: | Gastroenterology. 78:142-164 |
| ISSN: | 0016-5085 |
| Popis: | During the last two decades, the use of chemotherapeutic agents in the treatment of cancer and diverse medical conditions has grown steadily. The introduction into the pharmacologic armamentarium of a number of drugs whose pharmacokinetics, metabolism, and mode of action are in most cases poorly understood has not however been without causing problems to clinicians. Notably, the occurrence of clinical or biologic liver disturbances in patients treated with antineoplastic agents has become a challenging diagnosis and management problem. The purpose of this review is to assess what is currently known of the interrelation between some of the more commonly used or a few of the more recently acquired chemotherapeutic drugs and the liver. In the initial part of this work, the metabolic implication of the liver and, when reported, the liver toxicity of each of the drugs studied will be developed. Because experimental findings cannot always safely be extrapolated to humans, most of the presented data will be those obtained in human studies. The second part will propose a classification of the discussed agents in reference to hepatic involvement. Some practical attitudes will be suggested, and areas where our knowledge needs broadening will be pointed out. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|